Back to results
US 2017/0362656 A1Published application
miRNA-BASED UNIVERSAL SCREENING TEST (UST)
AssigneeDiamir, LLC
InventorsSamuil R. Umansky, Kira S. Sheinerman, Vladimir Tsivinsky
Life of this patent
Estimating the term…
Abstract
Described are methods for early noninvasive or minimally invasive detection of pathological changes in organ systems/organs/tissues/cells by quantifying organ system-/organ-/tissue-/cells type-enriched miRNA in bodily fluids.
Claims13
1-168. (canceled)
A method for selecting subjects for administering one or more disease-specific diagnostic tests to identify a specific pathology in an organ, which method comprises:
- a. for each of at least two different organs, measuring the level of one or more biomarker miRNAs in a bodily fluid sample collected from a subject of interest, wherein the bodily fluid is selected from the group consisting of blood plasma, serum, urine, and saliva;
- b. for each of the biomarker miRNAs measured in step (a), measuring the level of a normalizer miRNA in the same bodily fluid sample collected from the subject of interest;
- c. calculating the ratio of the level of the biomarker miRNA measured in step (a) to the level of the normalizer miRNA measured in step (b) for each of said organs;
- d. comparing the ratio calculated in step (c) with a corresponding control ratio for each of said organs, wherein the corresponding control ratio was determined in a corresponding bodily fluid collected from the subject of interest in the past, or from a different subject or a population of subjects without pathology of the respective organs, and
- e. administering one or more disease-specific diagnostic tests to the subject of interest when for at least one biomarker miRNA measured in step (a) the ratio calculated in step (c) is greater in the bodily fluid sample collected from the subject of interest than the corresponding control ratio.
2 more elements
Dependencies are inferred from the claim text.